Therapeutics for Women's Health Market Report 2015-2020: Technologies and Global Markets Analysis of the $40 Billion Industry
Dublin, July 27, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Therapeutics for Women's Health: Technologies and Global Markets" report to their offering.
The global market for women's health therapeutics will grow from nearly $33.0 billion in 2015 to nearly $40.6 billion by 2020, with a compound annual growth rate (CAGR) of 4.2% for the period of 2015-2020.
This report is an analytical business tool whose primary purpose is to describe the thorough evaluation of the global market for women's health therapeutics.
The format of the study is organized around the following topics:
- Detailed study around women's diseases such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and polycystic ovary syndrome (PCOS).
- Disease incidence and prevalence.
- Regulatory structure.
- Market characterization, unmet need, market size and segmentation.
- Market drivers and restraints.
- Detailed market projections through 2020.
- Competition and market shares.
- Pricing and reimbursement.
- Marketed and pipeline (R&D) products along with description, regulatory status and clinical trials.
- Observations and conclusions regarding the future of women's health therapeutics market.
- Profiles of market participants and associations.
This report provides:
- An overview of the global market for women's health therapeutics.
- Analyses of global market trends, with data from 2014, 2015, and projections of CAGRs through 2020.
- Information on women's health disorder types including infertility, endometriosis, postmenopausal osteoporosis, menopause, and polycystic ovary syndrome (PCOS).
- Detailed analysis of annual costs as well discussion on branded vs. generic options.
- Specifics on market factors such as drivers, restraints, and competition.
- Information on marketed as well as pipeline drugs and therapies.
- Profiles of major players in the industry.
Key Topics Covered:
Chapter 1: Introduction
Chapter 2: Summary
Chapter 3: Overview Of Women's Health Disorders
Chapter 4: Menopause-Related Symptoms And Diseases
Chapter 5: Postmenopausal Osteoporosis
Chapter 6: Endometriosis
Chapter 7: Polycystic Ovary Syndrome
Chapter 8: Breast Cancer
Chapter 9: Women's Health Disorder Therapeutics Market Assessment
Chapter 10: Competition And Market Shares
Chapter 11: Market Strategy
Chapter 12: Drug Pipeline Analysis
Chapter 13: Regulatory Structure
Chapter 14: Pricing And Reimbursement
Chapter 15: Conclusions-Outlook For Women's Health Therapeutics
Chapter 16: Company Profiles
Chapter 17: Industry And Professional Organizations
Chapter 18: Abbreviations
Companies Mentioned
- Abbvie
- Allergan
- Amgen
- Asahi Kasai
- Astellas Pharma Inc.
- Astrazaneca
- Bayer
- Bionovo
- Celgene
- Chugai Pharmaceuticals
- Depomed Inc.
- Eisai
- Eli Lilly
- Endoceutics
- Forendo Pharma Oy
- Glaxosmithkline
- Ipsen SA
- Les Laboratories Servier Sas
- Merck
- Mochida Pharma Co. Ltd.
- Meditrina Pharmaceuticals Inc.
- Neurocrine Biosciences Inc.
- Novartis AG
- Novo Nordisk A/S
- Novogyne Pharmaceuticals
- Oasmia Pharmaceutical
- Orion Pharma Ltd.
- Otsuka Holdings
- Paladin Labs Inc.
- Pfizer Inc.
- Preglem SA
- Puma Biotechnology
- Roche
- Radius Health Inc.
- Repros Therapeutics Inc.
- Sanofi
- Takeda Pharmaceutical
- Tarsa Therapeutics Inc.
- Teva Pharmaceutical Industries
- Therapeuticsmd
- Tsumura & Co.
- Warner Chilcott Corp. (Subsidiary Of Actavis)
- Ziopharm Oncology
- Zosano Pharma Inc.
For more information visit http://www.researchandmarkets.com/research/mtvgc8/therapeutics_for
CONTACT: Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Women's Health
© Copyright Globe Newswire. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Globe Newswire.
